Cognition Therapeutics, Inc. (CGTX) Wins Patent Extending CT1812 Protection to 2045

Cognition Therapeutics (CGTX) reported Q3 earnings, highlighting progress in its zervimesine drug trials for dementia with Lewy bodies (DLB) and Alzheimer's. The drug showed an 89% reduction in psychosis symptom progression in a Phase II study. The company expects cash to last into Q4 2027. Cognition also discussed cost reductions for upcoming trials and reported a net loss of $4.1 million for Q3.

Cognition Therapeutics reported a narrower net loss of $4.15M in Q3 2026, with EPS at ($0.04), compared to ($0.06) a year ago. The company had no revenue but saw higher grant income and lower administrative expenses. Clinical development is progressing, with FDA feedback aligning on a key study and Phase 2 trial enrollment completed. Cash reserves totaled $31.5M, expected to last into Q4 2027.

COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update - Management conference call at 8:30 a.m. ET today - Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company devel

Cognition Therapeutics (NASDAQ: CGTX) reported Q3 2026 results, aligning with FDA on endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB). The company also provided updates on its Phase 2 START study in Alzheimer's disease, with top-line results expected in 2H 2027. Financials included cash of $120.3M, R&D expenses of $20.1M, and a net loss of $25.2M. A conference call is scheduled for today.

Cognition Therapeutics (CGTX) aligned with the FDA on a Phase 3 study for zervimesine (CT1812) in dementia with Lewy bodies (DLB), a condition affecting 1.4 million Americans. The trial will assess 100 mg daily zervimesine vs. placebo over nine months, with primary endpoint measuring hallucinations and delusions. CGTX stock rose 1.74% to $0.74, and is up 7.02% in pre-market trading.

Cognition Therapeutics and the FDA agreed on the design for a Phase 3 trial of zervimesine for dementia with Lewy bodies. The trial will enroll patients with mild-to-moderate DLB, who will receive 100 mg of zervimesine or placebo for nine months. The primary endpoint will measure hallucinations and delusions. According to the company, there are no approved treatments for DLB.